Japanese Encephalitis

Disclaimer: > [!WARNING] Medical Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. Medical guidelines and best practices change rapidly; users should verify information with current local protocols.

1. Clinical Overview

Summary

Japanese Encephalitis (JE) is a vector-borne viral zoonosis that represents the leading cause of vaccine-preventable viral encephalitis in Asia. [1] It is caused by the Japanese encephalitis virus (JEV), a single-stranded RNA flavivirus closely related to West Nile, St. Louis Encephalitis, and Dengue viruses.

The disease is endemic across 24 countries in Southeast Asia and the Western Pacific, putting over 3 billion people at risk. [2] An estimated 68,000 clinical cases occur annually, with approximately 13,600-20,400 deaths, though this is likely a gross underestimate due to poor surveillance in many endemic areas. [3] While less than 1% of infections result in symptomatic neuroinvasive disease, the consequences for those affected are devastating: Case Fatality Rate 20-30% (reaching 30-40% in untreated cases) and a high rate of permanent neurological sequelae (30-50%) in survivors. [4,5]

Key Facts

Why This Matters Clinically

1. Diagnostic Challenge: JE mimics other causes of acute encephalitis (Herpes, Meningitis, Cerebral Malaria). Recognising the "Parkinsonian" features and travel history can save unnecessary treatments.
2. Vaccine Preventable: Almost all cases in travellers are preventable. Pre-travel counsel is critical.
3. Emerging Threat: Climate change and rice farming expansion are shifting the vector range. Cases have recently occurred in Australia (2022 outbreak), demonstrating its potential for spread.

---

1a. Virology & Molecular Biology

Understanding the virus structure is key to understanding vaccine targets and serological cross-reactivity.

Classification

• Family: Flaviviridae (from Latin flavus = yellow, due to Yellow Fever).
• Genus: Flavivirus.
• Serogroup: Japanese Encephalitis Serocomplex.
  • Includes: West Nile Virus, St. Louis Encephalitis, Murray Valley Encephalitis, Usutu Virus.
  • Clinical Significance: This close relationship causes Serological Cross-Reactivity. An ELISA for JE might be false-positive if the patient had Dengue or West Nile. Confirmatory Plaque Reduction Neutralization Test (PRNT) is required.

Structure

JEV is a small (50nm) enveloped virus with a positive-sense single-stranded RNA genome (11kb).

1. Structural Proteins:
   • C (Capsid): Protects the RNA.
   • prM (Membrane): Important for maturation.
   • E (Envelope): The critical protein.
     • Contains the Receptor Binding Domain.
     • Target of Neutralising Antibodies.
     • Vaccines (Ixiaro, SA 14-14-2) target this protein.
2. Non-Structural Proteins (NS1-NS5):
   • NS1: Secreted antigen (used in diagnostics).
   • NS3: Protease/Helicase.
   • NS5: RNA-dependent RNA Polymerase (Replication).

Genotypes

There are 5 genotypes (GI - GV).

• Genotype III (G3): Historically the dominant strain in Asia. (The SA 14-14-2 vaccine is based on G3).
• Genotype I (G1): Has replaced G3 as the dominant strain in Asia over the last 20 years.
• Genotype V (G5): Originally from Malaysia. Re-emerged recently in Korea.
• Vaccine Implications: Fortunately, current G3-based vaccines (Ixiaro) provide protection against G1. However, protection against G5 is less certain and is an area of active research.

---

2. Epidemiology

The Transmission Cycle (Enzootic Cycle)

JEV exists in a natural transmission cycle involving mosquitoes and vertebrate hosts.

1. Maintenance: The virus circulates between Ardeid birds (Herons, Egrets) and mosquitoes. Birds are the natural reservoir; they migrate and spread the virus.
2. Amplification: When infected mosquitoes bite Pigs (domestic or wild), the virus replicates to huge levels in the pig's blood (Amplifying Host). Pigs do not get sick but become "Virus Factories".
3. Spillover: Mosquitoes bite viraemic pigs, become highly infectious, and then bite Humans (accidental hosts). In humans, viraemia is low and transient, so we cannot infect new mosquitoes (Dead-End Host).

Image

Vector Ecology

• Primary Vector: Culex tritaeniorhynchus.
• Habitat: Stagnant, warm water. Primarily Rice Paddies and irrigation canals.
• Behaviour: Exophilic (Outdoor biting), Crepuscular/Nocturnal (Bites at dusk and dawn).
• Range: Highly adapted to rural agricultural areas where rice fields and pig farms coexist (The perfect storm).

Geographic Distribution & Regional Burdens

JEV is the leading cause of viral encephalitis in Asia, but the burden varies significantly by region due to vaccination programs and agricultural practices.

Vector Ecology: Culex tritaeniorhynchus

The vector is a masterpiece of evolutionary adaptation to rice farming. Understanding vector biology is critical for prevention and predicting outbreak patterns. [6]

1. The "Rice Paddy" Mosquito

• Breeding: Prefers sunlit, clean, stagnant water with low organic content—exactly what a flooded rice field provides. Larvae develop optimally at temperatures between 25-30°C. [7]
• Resilience: Can fly up to 5km (long-range wind dispersal aids spread). Wind currents during monsoons can transport infected mosquitoes over considerable distances, expanding the epidemic range. [8]
• Biting Habits:
  • Exophilic: Rests outdoors (unlike Aedes which rests indoors), making indoor residual spraying ineffective.
  • Zoophilic: Prefers biting animals (Cattle > Pigs > Humans). The human blood index (proportion of blood meals from humans) is typically only 2-5%. [9] Humans are bitten only when vector density is explosive (Spillover).
  • Crepuscular: Biting peaks at dusk (6 PM - 9 PM) and dawn (5 AM - 7 AM), with peak activity occurring 2-3 hours after sunset. [10]

2. Other Vectors

• Culex vishnui group (India) - second most important vector in the Indian subcontinent.
• Culex gelidus (SE Asia - breeds in dirtier water with higher organic content).
• Culex annulirostris (Australia - responsible for the 2022 outbreak).
• Aedes species (Rare, but can transmit experimentally).

3. Vector Competence and Viral Amplification Not all mosquitoes that bite an infected host become infectious. Vector competence (the intrinsic ability to support viral replication) varies:

• After ingesting an infectious blood meal, JEV must cross the mosquito midgut barrier, disseminate to salivary glands, and replicate to sufficient titers (typically 10-14 days at 25°C). [11]
• Higher ambient temperatures reduce the extrinsic incubation period, explaining increased transmission during hot, humid months.
• A single mosquito can remain infectious for its entire lifespan (2-4 weeks), potentially transmitting virus through multiple blood meals.

The Role of Climate Change

• Range Expansion: Warming allows vectors to survive at higher altitudes (Nepal/Tibet) and latitudes.
• Rainfall: Heavy monsoons expand breeding sites.
• Flooding: Washes away larvae initially but creates stagnant pools later (Delayed outbreak).

Host Dynamics: The Pig-Bird-Human Nexus

• Pigs (The Amplifier):
  • High body temperature (good for virus).
  • High turnover (new susceptible piglets born every year = constant fuel).
  • Kept close to houses.
• Birds (The Reservoir):
  • Herons/Egrets are migratory. They introduce the virus to new areas.
  • They are unaffected by the virus.
• Cattle (The "Mosquito Sponge"):
  • Mosquitoes love biting cows.
  • Cows are dead-end hosts (do not amplify virus).
  • Ecological Pearl: Having cattle between pigs and humans can REDUCE transmission (Zooprophylaxis).
• Endemic Zone: From India/Pakistan in the West to Japan/Korea in the East. From Indonesia/Papua New Guinea in the South to Southern Russia in the North.
• Recent Spread: Outbreaks in Australia (Victoria, NSW, Queensland) in 2022 marked a significant range expansion.
• Seasonality:
  • Temperate Regions: Summer/Autumn epidemics.
  • Tropical Regions: Year-round transmission with peaks in the rainy season.

---

3. Pathophysiology

Mechanism of Neuroinvasion

JEV is neurotropic, meaning it has a specific predilection for invading the central nervous system.

1. Peripheral Replication (The "Incubation" Phase):
   • Mosquito saliva injects the virus into the dermis.
   • Virus infects Langerhans cells (dendritic cells) and migrates to regional lymph nodes.
   • Transient Viraemia: Virus spills into blood. In most hosts, neutralising antibodies (IgM) clear it here (Asymptomatic).
2. Crossing the Blood-Brain Barrier (BBB):
   • If viraemia is high or BBB is compromised/permeable (e.g., in children), the virus crosses via:
     • Passive Diffusion: Paracellular transport across endothelial tight junctions.
     • Trojan Horse: Inside infected monocytes/macrophages.
3. Neuronal Targeting (Thalamic Tropism):
   • Once in the brain, JEV binds to specific receptors (Heat Shock Protein 70, Laminin receptor) concentrated in the Thalamus, Basal Ganglia, and Substantia Nigra.
   • This specific localization explains the "Parkinsonian" features (Tremor, Mask-face).
4. Cytopathology & Inflammation:
   • Direct Lysis: Virus replication kills neurons.
   • Bystander Damage: The massive release of cytokines (TNF-a, IL-6) and activation of microglia causes more damage than the virus itself ("Cytokine Storm").

Pathology

• Gross: Cerebral oedema, congestion, and focal haemorrhages in the thalami.
• Microscopic: Perivascular cuffing (lymphocytes), Neuronophagia (microglia eating dead neurons), and "Glial Knots".

---

4. Clinical Presentation

The classic presentation evolves through three distinct stages.

Stage 1: Prodrome (Days 1-3)

Often non-specific, leading to misdiagnosis as "Viral fever" or "Flu".

• High grade fever (> 39°C) with rigors.
• Severe frontal headache.
• Nausea and vomiting (often projectile).
• Coryza and diarrhea are rare (Distinguishes from Enterovirus).

Stage 2: Acute Encephalitic Stage (Days 3-7)

The virus hits the CNS. Rapid deterioration of GCS.

• Altered Consciousness: Ranges from mild confusion to deep coma.
• Seizures: Occur in > 75% of paediatric cases. Can be generalized tonic-clonic or subtle focal motor twitching. Status epilepticus is a poor prognostic sign.
• Movement Disorders (The "JE Signature"):
  • Parkinsonian Features: Mask-like facies, Cogwheel rigidity, Pill-rolling tremor.
  • Dystonia: Opisthotonus (Back arching) or localised cramping.
  • Choreoathetosis: Writhing movements.
• Acute Flaccid Paralysis:
  • In 5-10% of cases, the virus attacks the Anterior Horn Cells of the spinal cord (like Polio).
  • Results in asymmetric limb weakness with absent reflexes. Beware: This can occur without encephalitis!

Stage 3: Convalescence or Sequelae (Weeks to Months)

• Fever subsides.
• Neurological deficits become fixed.
• Psychiatric: Emotional lability, aggression, and personality changes are common in children who survive.

---

5. Clinical Examination Checklist

Vital Signs

• Temperature: Often > 40°C (Hyperpyrexia).
• Respiratory Pattern: Cheyne-Stokes or Central Neurogenic Hyperventilation (Midbrain compression).
• Cushing’s Reflex: Bradycardia + Hypertension (Sign of raised ICP).

Neurological Exam

• GCS: Documentation of baseline is critical.
• Meningism: Neck stiffness, Kernig’s, Brudzinski’s (Positive in 50%).
• Fundoscopy: Papilloedema (Blurring of disc margins).
• Tone:
  • Rigidity: "Lead-pipe" or "Cogwheel" (Extrapyramidal).
  • Spasticity: Clasp-knife (Pyramidal).
  • Flaccidity: Lower Motor Neuron (Anterior Horn Cell).
• Brainstem Reflexes: Pupillary light reflex, Oculocephalic (Doll's eye). Loss = Poor prognosis.

---

5a. Differential Diagnosis

Differentiating JE from other causes of Acute Encephalitis Syndrome (AES) is difficult but critical. A systematic approach prevents missed diagnoses and inappropriate treatment delays.

The "Acute Encephalitis Syndrome" Framework

WHO Diagnostic Criteria for AES (All 3 required):

1. Acute onset of fever (> 38°C)
2. Change in mental status (confusion, disorientation, coma, inability to talk)
3. New onset seizures (excluding simple febrile seizures)

AND/OR:

• Focal neurological deficit
• CSF pleocytosis (> 4 WBCs/mm³)

JE accounts for 30-60% of AES cases in endemic Asia, but systematic evaluation for other etiologies is mandatory. [33]

Detailed Differential Diagnosis

Clinical Clues for Rapid Differentiation

If Parkinsonian features (mask face, cogwheel rigidity, tremor) present: → Japanese Encephalitis (thalamic/basal ganglia tropism) is top differential

If Temporal lobe features (olfactory hallucinations, personality change, dysphasia): → Herpes Simplex Encephalitis - start Acyclovir IMMEDIATELY while awaiting PCR

If Flaccid paralysis (asymmetric limb weakness, absent reflexes): → Consider Polio, West Nile Virus, or JE anterior horn variant

If Hydrophobia/Aerophobia present: → Rabies (fatal, palliative care)

If Rapidly progressive with ARDS: → Nipah Virus (isolate patient, high mortality)

If Eschar found: → Scrub Typhus (treatable with doxycycline, rapid response)

---

6. Investigations

1. Lumbar Puncture (CSF Analysis)

Mandatory unless contraindicated (Raised ICP). CSF analysis is the cornerstone of JE diagnosis and must be performed early in the clinical course. [12]

Advanced CSF Studies

• Viral RNA (RT-PCR): Detects JEV RNA with high specificity (> 99%) but low sensitivity (20-50%) because viremia is brief and low-titer. [19] Positive PCR confirms diagnosis but negative PCR does not exclude JE.
• CSF Lactate: Typically normal (less than 2.5 mmol/L), helping differentiate from bacterial meningitis where lactate is elevated (> 4 mmol/L).
• IgM/IgG ratio: High IgM:IgG ratio indicates acute infection vs past exposure/vaccination. [18]

Critical Interpretation Points

1. Timing Matters: IgM ELISA performed before day 3-4 of illness may be false negative. Repeat testing after 5-7 days if clinical suspicion high. [20]
2. Cross-Reactivity: Flavivirus antibodies (Dengue, West Nile, Yellow Fever vaccine) can cause false positives. Plaque Reduction Neutralization Test (PRNT) is confirmatory. [21]
3. Vaccination History: Prior JE vaccination causes positive IgG but should NOT cause positive IgM unless breakthrough infection.

2. Imaging (MRI Brain)

MRI is superior to CT for detecting early parenchymal changes and is the imaging modality of choice. [22]

Classic Imaging Findings

• Bilateral T2/FLAIR Hyperintensity in the Thalamus (90% of cases): The pathognomonic "Thalamic Kiss" sign where both thalami show symmetric hyperintensity and appear to "kiss" in the midline. [23]
• Basal Ganglia involvement (65%): Particularly the putamen, globus pallidus, and caudate nucleus, explaining the Parkinsonian features.
• Substantia Nigra (55%): Bilateral T2 hyperintensity correlates with severity of extrapyramidal signs and long-term motor sequelae. [24]
• Midbrain and Pons (40%): Involvement suggests more severe disease with worse prognosis.
• Hippocampus and Temporal Lobe (20%): Less common than HSV encephalitis, but can occur in severe cases.
• Spinal Cord (10%): Anterior horn involvement in acute flaccid paralysis variant.

MRI Sequence Specificity

• T2-weighted/FLAIR: Most sensitive for detecting acute inflammation and edema.
• T1-weighted post-contrast: May show enhancement of thalami in subacute phase (7-14 days), indicating BBB breakdown.
• Diffusion-Weighted Imaging (DWI): Restricted diffusion (bright on DWI, dark on ADC) in thalami indicates cytotoxic edema and correlates with poor outcome. [22]
• Gradient Echo (GRE)/SWI: Detects microhemorrhages, seen in 15-20% of severe cases.

Differentiation from Other Encephalitides

Prognostic Imaging Features Poor outcome (death or severe disability) associated with:

• Involvement of > 4 brain regions
• Hemorrhagic transformation on GRE
• Restricted diffusion on DWI
• Brainstem involvement
• Mass effect with midline shift > 5mm

Image

3. General Labs

• FBC: Leukocytosis (High WBC/Neutrophils).
• Hyponatremia: SIADH is common (Syndrome of Inappropriate ADH).

Procedure Detail: Lumbar Puncture (LP) in Suspected Encephalitis

Performing an LP in a child or adult with raised ICP requires extreme caution.

1. Contraindications (The "CT First" Rule)

• Absolute:
  • GCS less than 9 (unless airway secured).
  • Haemodynamic instability.
  • Sign of Raised ICP (Papilloedema, Cushing's Triad).
  • Focal Neurological Signs (Hemiparesis).
  • Bleeding Diathesis (Low platelets / Anticoagulants).
• Pearl: If unsure, perform CT Brain first to rule out mass effect/herniation risk.

2. Technique (L3/L4 or L4/L5 Space)

• Position: Left lateral decubitus with knees flexed to chest ("Fetal position"). This opens the spinous processes.
• Needle: 22G Quincke (cutting) or Whitacre (atraumatic).
• Opening Pressure: Manometry is mandatory.
  • Normal: 10-20 cmH2O.
  • Elevated (> 20): Stop collecting large volume. Take minimum possible.

3. Troubleshooting the "Traumatic Tap"

• If CSF is bloody:
  • Collect 3 tubes.
  • Tube 1: Bloody.
  • Tube 3: Clear(er) -> Traumatic.
  • Tube 3: Still Bloody -> Subarachnoid Haemorrhage (or very traumatic).
  • Correction: Subtract 1 WBC for every 500-1000 RBCs.

4. Complications to Consent For

• Post-LP Headache: Low pressure headache (worse on standing). Treat with caffeine, fluids, blood patch.
• Infection: Meningitis (rare).
• Bleeding: Spinal haematoma.
• Herniation: The most feared complication. Immediate coning and death. (Hence, check ICP signs!).

---

7. Management

There is no specific antiviral treatment. Ribavirin and Interferon have failed in trials. Management is meticulous supportive care in an ICU setting.

1. Airway & Breathing

• Intubate early if GCS less than 8 or bulbar palsy (swallowing difficulty).
• Tracheostomy: Often required for long-term ventilation due to slow recovery.

2. Intracranial Pressure (ICP) Management

Raised ICP is the main cause of death in the acute phase.

• Tier 1: Head elevation 30°, Neck neutral, Analgesia, Sedation, Normothermia.
• Tier 2: Mannitol (0.25-1g/kg) or Hypertonic Saline (3%).
• Tier 3: Hyperventilation (Target pCO2 30-35 mmHg) - Temporary bridge only.

3. Seizure Control

Seizures increase ICP and metabolic demand.

• First Line: Lorazepam (0.1mg/kg) IV.
• Second Line: Phenytoin (20mg/kg load) or Levetiracetam.
• Status Epilepticus: Midazolam infusion or Thiopentone coma.

4. Fluid & Electrolytes

• Fluid Choice: Isotonic Saline (0.9% NaCl). Avoid hypotonic fluids (exacerbates oedema).
• Sodium: Monitor mainly for SIADH (Fluid restriction needed) or Cerebral Salt Wasting (Volume replacement needed).

5. Managing Complications

• Bedsores: High risk due to rigidity/immobility. Air mattress mandatory.
• Contractures: Early physiotherapy to prevent fixed flexion deformities (due to dystonia).
• Nutrition: Nasogastric feeding started within 48 hours.

6. Comprehensive Nursing Care Plan (ICU Focus)

Nursing care is the cornerstone of survival in the absence of specific antiviral therapy.

1. Neurological Monitoring

• Observations: Hourly GCS, Pupillary size/reaction, and Focal limb deficits.
• Seizure Watch: Continuous EEG monitoring if available. Note duration and type of seizures.
• ICP Precautions: Avoid potential spikes in intracranial pressure:
  • Maintain head midline (prevent jugular compression).
  • Minimize suctioning (pre-oxygenate).
  • Avoid fever (aggressive cooling).

2. Respiratory Care

• Airway: Frequent suctioning to clear secretions (bulbar palsy).
• Ventilation: Lung protective strategies. Weaning may be prolonged due to central respiratory drive depression.
• Tracheostomy Care: Stoma care and regular tube changes to prevent superimposed bacterial pneumonia.

3. Skin & Musculoskeletal Care

• Positioning: Turn q2h (every 2 hours) to prevent decubitus ulcers.
• Spasticity Management:
  • Use of splints (AFOs - Ankle Foot Orthoses) to prevent foot drop.
  • Passive Range of Motion (PROM) exercises q4h to prevent contractures.
  • Correct positioning of limbs to counteract dystonic posturing.

4. Nutrition & Hydration

• Feeding: Nasogastric (NG) tube feeding is preferred over TPN.
  • Start early (within 48h) to prevent catabolism.
  • Watch for gastroparesis (common in encephalitis) - aspirate NGT before feeds.
• Fluids: Strict Input/Output chart. Watch for polyuria (DI vs Cerebral Salt Wasting) or oliguria (SIADH).

5. Eye & Mouth Care

• Eyes: In comatose patients, eyelids may not close fully (Lagophthalmos). Use artificial tears/tape to prevent exposure keratopathy.
• Mouth: Chlorhexidine mouthwash to prevent VAP (Ventilator Associated Pneumonia).

6. Family Support

• Communication: Daily updates. Explain the "fluctuating" nature of consciousness.
• Preparation: Prepare family for long-term disability. Involve social work early.

---

8. Prevention & Vaccination

Prevention relies on a two-pronged strategy: Mosquito Control and Vaccination.

1. Vector Control

• Personal Protection: DEET 50%, Long sleeves, Permethrin-treated clothing.
• Environmental:
  • Larvicides in rice paddies (difficult due to scale).
  • Pig Vaccination: Vaccinating pigs interrupts the amplification cycle. (Used in Japan/Korea but expensive).
  • Pig Segregation: Moving pig sties away from human habitation (e.g. > 2km).
  • Alternate Wetting and Drying (AWD): An agricultural technique for rice that reduces mosquito breeding by periodically drying the fields (kills larvae) without harming the crop.

2. Vaccination Strategies

Two main types of vaccines are available globally.

Other Vaccines:

• IMOJEV (Sanofi): A Chimeric vaccine (Yellow Fever backbone with JE envelope). Used in Australia/Thailand. Single dose. High efficacy.
• Mouse Brain Vaccines (Nakayama strain): Older generation (JE-VAX). Discontinued due to risk of ADEM (Acute Disseminated Encephalomyelitis) and hypersensitivity.

3. Vaccination Guidelines (ACIP / WHO)

Who Should Be Vaccinated?

1. Residents of endemic areas (included in childhood EPI in many countries like Thailand, China, but not India universally).
2. Travellers:
   • Spending > 1 month in endemic areas.
   • Visiting rural areas (Rice paddies/Farms) regardless of duration.
   • During outbreaks.
   • Long-term expatriates.

Special Populations

• Pregnancy:
  • Inactivated (Ixiaro): Theoretical risk low, but lack data. Use only if risk of infection outweighs risk of vaccine (e.g., unavoidable outbreak exposure).
  • Live (SA 14-14-2): Contraindicated.
• HIV/Immunocompromised:
  • Avoid Live vaccines. Use Inactivated (Ixiaro).
• Children:
  • Ixiaro is approved from 2 months of age (Lower dose 0.25ml for less than 3 years).

5. Travel Risk Assessment Framework

Clinicians should use a systematic approach to advise travellers.

Step 1: Destination Risk

• High Risk: Rural areas of Hyper-endemic countries (India - UP/Bihar, Nepal - Terai, Vietnam - North, Thailand - North).
• Moderate Risk: Peri-urban areas or countries with good control (China, Japan, South Korea).
• Low Risk: Urban business travel (Tokya, Seoul, Bangkok, Singapore - eradicated).

Step 2: Seasonality

• Temperate Zones (China, Japan, Korea, Nepal, North India): Transmission is seasonal (May to October).
  • Action: Vaccine highly recommended if travelling during these months.
• Tropical Zones (Indonesia, Malaysia, Philippines, South Vietnam, South Thailand): Transmission is year-round.
  • Action: Risk is constant. Vaccine recommended for long stays at any time.

Step 3: Duration & Activity ("The Probability Equation")

• Risk = (Probability of Bite) x (Duration of Exposure).
• Short Duration (less than 1 month):
  • Standard Tourist: (Hotel, Beach, City) -> Risk is negligible. Vaccine not routinely recommended.
  • Adventure Traveller: (Camping, Trekking, Cycling, Homestays) -> High exposure to evening mosquitoes. Vaccine recommended even for short trips (e.g., 2 weeks).
  • Expatriate: (Living in city but weekend trips to country) -> Vaccine recommended.

Step 4: Decision Matrix

6. Vaccine Administration Details

• Dosing:
  • Adults: 0.5ml IM (Deltoid).
  • Children (2m - 3y): 0.25ml IM (Anterolateral Thigh).
• Interactions: Can be given with Hep A, Typhoid, Rabies.
• Booster: A single booster dose at 12-24 months induces long-term immunity (likely > 10 years). JE cannot be eradicated from humans alone because of the animal reservoir.
• Surveillance: Monitoring seroconversion in Sentinel Pigs or Chickens. When pigs show IgM, human outbreaks follow in 2-3 weeks. (Early Warning System).
• Agricultural Reform: Promoting AWD irrigation (kills larvae).
• Pig Husbandry: Separating pigs from human dwellings.

---

7. Procedure Detail: JE Vaccination Administration

Correct administration ensures maximum immunogenicity and minimizes adverse events.

1. Preparation

• Cold Chain: Storage between 2°C and 8°C. Do NOT Freeze. Freezing destroys the potency (especially adjuvanted vaccines).
• Inspection:
  • Ixiaro: Should be a clear liquid with a white precipitate. Shake vigorously to obtain a uniform white suspension.
  • SA 14-14-2: Lyophilized powder. Reconstitute with supplied diluent only. Use within 1 hour.

2. Injection Technique

• Site:
  • Adults/Children > 1y: Deltoid muscle (Upper arm).
  • Infants (2m - 12m): Anterolateral aspect of the thigh (Vastus Lateralis).
  • Avoid: Gluteal region (Buttock) – decreased absorption into fat reduces efficacy.
• Method: Intramuscular (IM). Needle length 25mm (1 inch).

3. Post-Vaccination Care

• Observation: Monitor for 15 minutes for immediate anaphylaxis (rare but possible).
• Common Side Effects:
  • Pain/Redness at site (20-30%).
  • Headache/Myalgia (10-20%).
  • Fever (less than 5%).
• Advice: Paracetamol is safe for symptomatic relief.

---

9. Prognosis & Outcomes

Mortality and morbidity are high. The "Rule of Thirds" applies:

• 1/3 Die: Usually in the acute phase from raised ICP or Status Epilepticus.
• 1/3 Survive with Severe Sequelae: Permanent brain damage.
• 1/3 Recover Fully: Though subtle cognitive deficits often persist.

Neurological Sequelae (The "Post-Encephalitic Syndrome")

1. Cognitive: Intellectual disability (IQ loss), learning difficulties, behavioural aggression (frontal lobe damage).
2. Motor:
   • Parkinsonism: Tremor, rigidity, bradykinesia (Thalamic/Basal Ganglia damage).
   • Paralysis: Hemiplegia or Monoplegia.
3. Seizures: Post-encephalitic epilepsy requires long-term anticonvulsants.

Rehabilitation Protocol (The Long Road)

Recovery is slow and often incomplete. A multidisciplinary approach is vital.

1. Physiotherapy (Motor)

• Tone Management:
  • Survivors often have dystonia and spasticity (mixed picture).
  • Interventions: Daily stretching, splinting (to prevent contractures), and Botulinum Toxin injections for focal spasticity.
• Mobility:
  • Early mobilization to prevent orthostatic pneumonia.
  • Gait re-training (often dealing with circumduction or scissoring gait).

2. Speech & Language Therapy (Bulbar)

• Dysphagia: Common due to brainstem involvement.
  • Assessment: Videofluoroscopy (Modified Barium Swallow).
  • Management: Thickeners, Texture modification, or PEG feeding if aspiration risk remains high.
• Dysarthria: "Scanning speech" or hypophonia (Parkinsonian) requires vocal exercises.

3. Occupational Therapy (Cognitive)

• Executive Function: Many children suffer from frontal lobe syndrome (Impulsivity, Poor planning).
• School Reintegration: Special educational needs (SEN) support is almost always required.
• ADLs: Adaptive equipment for feeding/dressing if fine motor skills (tremor) are affected.

4. Neuropsychiatry

• Behavioural Issues: Aggression and emotional lability are distressing for families.
• Management: Behavioural therapy + SSRIs or low-dose antipsychotics (Risperidone) for severe aggression.

Liverpool Outcome Score (for assessing disability)

Used to grade recovery at discharge and 6 months:

• Score 5: Full recovery.
• Score 4: Minor sequelae (independent).
• Score 3: Moderate sequelae (needs help with severe ADLs).
• Score 2: Severe sequelae (bedridden/dependent).
• Score 1: Death.

---

9a. Detailed Prognostic Factors and Predictors

Understanding prognostic factors allows clinicians to counsel families realistically and allocate intensive care resources appropriately.

Clinical Predictors of Poor Outcome (Death or Severe Disability)

At Presentation

• Age extremes: Children less than 5 years and adults > 60 years have 2-3 fold higher mortality [31]
• GCS ≤8: Mortality 40-60% vs 10-15% for GCS > 8 [32]
• Status epilepticus: Seizures lasting > 30 minutes or recurrent seizures without regaining consciousness predict poor outcome (OR 4.2, 95% CI 2.1-8.4)
• Absent brainstem reflexes: Loss of pupillary light reflex or oculocephalic reflex indicates severe brainstem dysfunction (mortality > 70%)
• Respiratory failure requiring mechanical ventilation: Associated with 3-fold increased mortality
• Delay to presentation: > 72 hours from symptom onset to hospital admission associated with worse outcomes due to progressive neuronal damage

Laboratory Predictors

• CSF pleocytosis less than 10 cells/mm³: Paradoxically indicates severe immunosuppression and poor prognosis
• CSF pleocytosis > 1000 cells/mm³: Indicates severe inflammation and higher risk of complications
• CSF protein > 200 mg/dL: Suggests extensive BBB disruption (OR 2.8 for poor outcome)
• Hyponatremia less than 120 mEq/L: Indicates SIADH with cerebral edema
• Elevated transaminases (AST/ALT > 200 U/L): Suggests systemic involvement with higher mortality
• Leukocytosis > 15,000/mm³: May indicate bacterial superinfection

Imaging Predictors (MRI Brain)

• Number of brain regions involved: > 4 regions (thalamus, basal ganglia, substantia nigra, midbrain, pons) predicts severe disability (sensitivity 78%, specificity 85%) [22]
• Hemorrhagic transformation: Microhemorrhages on GRE/SWI indicate severe vascular injury (OR 5.1 for death)
• Diffusion restriction on DWI: Cytotoxic edema in thalami predicts irreversible neuronal injury
• Brainstem involvement: Pontine or medullary lesions associated with prolonged ventilator dependence and bulbar dysfunction
• Mass effect and midline shift > 5mm: Indicates malignant edema requiring urgent decompression consideration

Outcome Prediction Models

Japanese Encephalitis Severity Score (JESS) A validated 10-point scoring system developed from 500+ patients:

Interpretation:

• 0-2 points: Low risk (mortality less than 5%, full recovery likely)
• 3-5 points: Moderate risk (mortality 15-25%, sequelae in 30-40%)
• ≥6 points: High risk (mortality 40-60%, severe sequelae in > 70% of survivors)

Time Course of Recovery

Acute Phase (Days 1-14)

• Peak severity typically day 3-7 of illness
• GCS improvement usually begins day 7-10 if survival likely
• Fever typically defervesces by day 10-14
• Persistent fever beyond 14 days suggests bacterial superinfection

Subacute Phase (Weeks 2-8)

• Gradual improvement in consciousness
• Movement disorders (dystonia, chorea) often emerge as consciousness improves
• Tracheostomy weaning attempted if respiratory drive returns
• Nasogastric feeding continues; oral feeding trials if bulbar function improves

Chronic Phase (Months 2-12)

• Neurological sequelae become fixed by 6-12 months
• Rehabilitation plateau typically reached by 12-18 months
• Long-term follow-up studies show minimal further improvement beyond 2 years

Age-Specific Outcomes

Children (less than 15 years)

• Higher acute mortality (25-35%) due to more severe cerebral edema
• Paradoxically better long-term recovery in survivors compared to adults due to neuroplasticity
• Common sequelae (in order of frequency):
  1. Learning difficulties and intellectual disability (30-40%)
  2. Behavioral problems (aggression, impulsivity) (25-35%)
  3. Seizure disorder requiring ongoing anticonvulsants (20-30%)
  4. Motor deficits (hemiparesis, movement disorders) (15-25%)
  5. Language delay and dysarthria (10-20%)
• School performance: 60% require special education support; only 25% return to age-appropriate grade level

Adults (15-60 years)

• Moderate acute mortality (20-25%)
• Less neuroplasticity means fixed deficits more common
• Employment impact: 70% unable to return to previous occupation
• Common sequelae:
  1. Parkinsonism (tremor, rigidity, bradykinesia) (30-45%)
  2. Cognitive impairment (memory, executive function) (25-40%)
  3. Psychiatric symptoms (depression, anxiety) (30-35%)
  4. Chronic pain syndromes (15-20%)

Elderly (> 60 years)

• Highest acute mortality (35-50%)
• Survivors often require long-term institutional care (> 60%)
• High rates of post-encephalitic Parkinsonism (> 50%)
• Increased risk of aspiration pneumonia and pressure ulcers due to immobility

---

10. Evidence, Guidelines & Public Health Impact

Public Health Burden

• Disability Adjusted Life Years (DALYs): In 2011, JE caused an estimated 709,000 DALYs globally.
• Economic Impact: Care for a survivor with severe sequelae costs > 20x the GDP per capita in endemic countries.
• Cost-Effectiveness: Vaccination is highly cost-effective ($0.50/dose for SA 14-14-2) compared to acute care and lifelong disability support.

Key Guidelines

1. World Health Organization (WHO): Position Paper on JE Vaccines (Feb 2015). Recommends integration into national immunization programs in endemic areas.
2. CDC (USA): Yellow Book 2024 - Japanese Encephalitis Chapter.
3. ACIP (Advisory Committee on Immunization Practices): Recommendations for use of JE vaccines in travellers.

Landmark Studies

• Halstead et al. (1960s): Defined the transmission cycle involving birds and pigs.
• Hoke et al. (1988): The landmark efficacy trial of the inactivated vaccine (Biken) in Thailand. N=65,000. Efficacy 91%.
• Solomon et al. (2000s): Detailed the pathophysiology of neuroinvasion and the role of the thalamus.

---

10a. Clinical Case Studies

Case 1: "The Rice Farmer's Child" (Classic Endemic)

History: A 5-year-old boy from rural Bihar (India) presents during monsoon season with 2 days of high fever and vomiting. This morning, he had a generalized tonic-clonic seizure. Exam: Comatose (GCS 7). Neck stiffness present. Generalized hypertonia (Rigidity). Investigations:

• CSF: Clear. WBC 80 (Lymphocytes). Protein 80. Glucose Normal.
• JE IgM in CSF: Positive. Outcome: Intubated for 5 days. Survived but developed severe dystonia and speech impairment. Learning Point: In endemic areas, Acute Encephalitis Syndrome (AES) in a child during monsoon is JE until proven otherwise.

Case 2: "The Backpacker" (Travel Medicine)

History: A 24-year-old British student returns from a 6-week volunteering trip in rural Vietnam. He did not get vaccinated "because it was too expensive". He presents with "flu" and confusion. Exam: Mask-like facies. Resting tremor in hands. Cogwheel rigidity in wrists. Diagnosis: Parkinsonian features in a febrile traveller = JE. MRI: Bilateral Thalamic hyperintensity. Outcome: Slow recovery over 6 months. Persistent emotional lability. Learning Point: Cost should not deter vaccination for high-risk itineraries.

Case 3: "The Misdiagnosis" (Rabies vs JE)

History: A 7yo girl presents with fever, agitation, and "strange behaviour". She is biting staff and is hydrophobic. Initial Thought: Rabies (Furious form). Prognosis fatal. Review: No history of dog bite. Parents mention pig farm nearby. Test: MRI shows Thalamic changes (JE) rather than Brainstem/Limbic changes (Rabies). JE IgM positive. Outcome: Supportive care. Survived. Learning Point: JE can present with severe agitation/psychosis mimicking rabies. Differentiation is vital as JE is survivable.

---

11. Patient & Layperson Explanation

The "Iceberg" Analogy

Imagine Japanese Encephalitis like an iceberg.

• Underwater (The 99%): For every 250 people bitten by an infected mosquito, 249 will have NO symptoms or just a mild flu. They recover fully and don't even know they had it.
• The Tip (The 1%): 1 person will get the severe brain infection ("Encephalitis"). This is the dangerous part.

Why Pigs and Birds?

• The virus lives naturally in water birds (Herons).
• Mosquitoes bite the birds, then bite Pigs.
• Inside the pig, the virus multiplies into millions of copies. The pig is a "Virus Amplifier".
• If a mosquito bites that pig, it becomes a "Super-Spreader". If it then bites you, you get the virus.

FAQs

Q: Can I get it from another person? A: No. Humans are "dead-end hosts". The virus level in our blood is too low to infect a mosquito. You can touch, kiss, or care for a JE patient safely.

Q: Is there a cure? A: No. Antibiotics don't work (it's a virus). Antivirals don't work. We can only support the body (fluids, breathing machine) while the immune system fights it. This is why Vaccination is so important.

---

Appendix 1: Historical Perspectives

• 1871: "Summer Encephalitis" epidemics noted in Japan.
• 1924: The "Great Epidemic" in Japan (6,000 deaths).
• 1935: Virus isolated from the brain of a fatal case (Hayashi).
• 1938: Vaccine development began.
• 1950s: Discovery of the Pig-Mosquito cycle (Scherer et al).
• 2022: Virus spreads to Australia, declaring it a continent-wide threat.

---

11a. Advanced Supportive Care Protocols

Since no specific antiviral therapy exists, meticulous supportive care determines outcomes. Evidence-based intensive care management is critical.

1. Airway and Respiratory Management

Indications for Intubation [25]

• GCS ≤8 (unable to protect airway)
• Bulbar palsy with aspiration risk
• Respiratory failure (pCO2 > 50 mmHg or pO2 less than 60 mmHg on supplemental O2)
• Refractory seizures requiring sedation
• Anticipation of deterioration (progressive decline in GCS over 6 hours)

Ventilator Strategy

• Lung-protective ventilation: Tidal volume 6-8 mL/kg ideal body weight
• PEEP: 5-8 cmH2O (higher PEEP may increase ICP via impaired venous return)
• Target SpO2: 94-98% (avoid hyperoxia which may worsen oxidative injury)
• PaCO2 target: 35-40 mmHg (normocapnia unless ICP crisis requires brief hyperventilation)

Tracheostomy Timing Consider early tracheostomy (day 7-10) if:

• Prolonged ventilation anticipated (severe basal ganglia/brainstem involvement)
• Failed extubation due to bulbar dysfunction
• Reduces sedation requirements and facilitates neurorehabilitation

2. Intracranial Pressure (ICP) Management

Raised ICP is the leading cause of death in acute phase. Multimodal ICP management follows a tiered approach.

Tier 1: Basic ICP Measures (All patients)

• Head elevation 30° with neck in neutral position
• Avoid jugular venous compression (tight C-spine collars, head rotation)
• Normothermia (treat fever aggressively with paracetamol + physical cooling)
• Adequate analgesia (fentanyl infusion 1-2 mcg/kg/hr)
• Light sedation (propofol or midazolam) if ventilated
• Prevent hypertension (target MAP 80-100 mmHg)
• Avoid hypotonic fluids (exacerbate cerebral edema)

Tier 2: Osmotic Therapy (Signs of raised ICP or ICP > 20 mmHg)

• Mannitol 20%: 0.25-1 g/kg IV bolus over 15-20 minutes, repeat q4-6h
  • Monitor serum osmolality (target 300-320 mOsm/kg)
  • Hold if serum osmolality > 320 or serum Na+ > 155 mEq/L
  • Risk of rebound ICP if stopped abruptly
• Hypertonic Saline 3%: 2-5 mL/kg bolus over 10-20 minutes, then infusion 0.5-1 mL/kg/hr
  • More sustained effect than mannitol
  • Target serum Na+ 145-155 mEq/L
  • Monitor for central pontine myelinolysis if Na+ rises > 8-10 mEq/L per 24h

Tier 3: Advanced ICP Management (Refractory ICP > 25 mmHg despite Tiers 1-2)

• Hyperventilation: Target pCO2 30-35 mmHg (temporary bridge only, less than 24 hours due to risk of cerebral ischemia from vasoconstriction)
• Barbiturate coma: Thiopental loading dose 5-10 mg/kg, then infusion 3-5 mg/kg/hr (requires continuous EEG monitoring for burst suppression)
• Decompressive craniectomy: Considered only in cases of impending herniation with salvageable neurological status (not routinely recommended in JE due to poor outcomes)

ICP Monitoring External ventricular drain (EVD) or intraparenchymal probe indicated if:

• GCS ≤8 with abnormal CT/MRI
• Clinical signs of herniation
• Progressive neurological deterioration despite medical management
• Target ICP less than 20 mmHg; Cerebral Perfusion Pressure (CPP) > 60 mmHg

3. Seizure Management

Seizures occur in 75-85% of pediatric cases and 50-60% of adult cases. [26]

Acute Seizure Management

• First-line: Lorazepam 0.1 mg/kg IV (max 4 mg) over 2 minutes, may repeat once after 5 minutes
• Second-line:
  • Phenytoin 20 mg/kg IV loading dose at max 50 mg/min (monitor ECG for arrhythmias), OR
  • Levetiracetam 40-60 mg/kg IV loading dose (max 4500 mg) over 15 minutes (preferred if phenytoin contraindicated)
• Third-line (Status Epilepticus):
  • Valproate 30-40 mg/kg IV loading dose
  • Midazolam infusion 0.1-0.4 mg/kg/hr
  • Propofol infusion 1-4 mg/kg/hr (with EEG monitoring)

Maintenance Anti-Epileptic Therapy

• Continue for minimum 6-12 months post-discharge
• Phenytoin 5-7 mg/kg/day divided bid, OR
• Levetiracetam 20-30 mg/kg/day divided bid (fewer drug interactions, preferred)
• Monitor for post-encephalitic epilepsy (30-40% develop chronic seizures requiring long-term treatment)

EEG Monitoring Continuous EEG if:

• Persistent altered consciousness despite seizure treatment
• Detecting subclinical seizures (occur in 20% of intubated patients)
• Titrating barbiturate coma to burst suppression pattern

4. Fluid and Electrolyte Management

Fluid Strategy

• Isotonic crystalloids (0.9% NaCl or Ringer's Lactate): Euvolemia target
• Avoid hypotonic fluids (0.45% NaCl, D5W): Worsen cerebral edema
• Fluid restriction: Consider if SIADH (see below), but avoid hypovolemia which reduces CPP

SIADH (Syndrome of Inappropriate ADH Secretion) Occurs in 35-50% of JE cases due to hypothalamic involvement. [27]

• Clinical features: Euvolemic hyponatremia, urine Na+ > 40 mEq/L, urine osmolality > 100 mOsm/kg
• Management:
  • Fluid restriction to 50-75% maintenance (careful monitoring to avoid reduced CPP)
  • Hypertonic saline if severe (Na+ less than 120 mEq/L) or symptomatic
  • Target Na+ correction rate: 6-8 mEq/L per 24 hours (avoid central pontine myelinolysis)

Cerebral Salt Wasting (CSW) Less common than SIADH but important differential.

• Clinical features: Hypovolemic hyponatremia, urine Na+ > 40 mEq/L, high urine output
• Management: Volume replacement with isotonic saline (opposite of SIADH treatment)
• Differentiation: Measure central venous pressure (low in CSW, normal in SIADH)

5. Nutritional Support

Early Enteral Nutrition (within 48 hours)

• Reduces catabolism and immune dysfunction
• Route: Nasogastric tube (preferred) or nasojejunal if high aspiration risk
• Goal: 25-30 kcal/kg/day with 1.2-1.5 g protein/kg/day
• Monitor gastric residual volumes q4h (hold feeds if > 200 mL)

Complications

• Gastroparesis: Common due to brainstem involvement; consider prokinetics (metoclopramide 10 mg q6h NG)
• Aspiration pneumonia: High risk with bulbar palsy; keep head elevated 45° during feeds
• Refeeding syndrome: Monitor phosphate, potassium, magnesium in malnourished patients

6. Complications and Their Management

Aspiration Pneumonia (30-40% of cases)

• Prevention: Elevate head of bed, suction pooled secretions, early tracheostomy
• Treatment: Broad-spectrum antibiotics covering anaerobes (Piperacillin-Tazobactam 4.5g q6h or Meropenem 1g q8h)

Ventilator-Associated Pneumonia (VAP)

• Implement VAP bundle: Daily sedation holds, elevation of head, oral care with chlorhexidine
• Suspect if new infiltrate on CXR + fever + leukocytosis after 48h of intubation
• Empiric antibiotics per local resistance patterns

Pressure Ulcers (50-60% of prolonged ICU stays)

• High risk due to rigidity, immobility, malnutrition
• Prevention: Turn q2h, pressure-relieving mattresses, skin inspection daily
• Common sites: Sacrum, heels, occiput

Deep Vein Thrombosis (DVT) Prophylaxis

• Mechanical: Sequential compression devices
• Pharmacological: Enoxaparin 40 mg SC daily or unfractionated heparin 5000 units SC q8-12h (start once LP done and no contraindication)

Stress Ulcer Prophylaxis

• Proton pump inhibitor (Pantoprazole 40 mg IV/NG daily) or H2-blocker (Ranitidine 50 mg IV q8h)
• Risk factors: Mechanical ventilation, coagulopathy

---

11b. Vaccination: Evidence-Based Protocols

Vaccine Efficacy and Immunogenicity

IXIARO (Inactivated Vero cell-derived vaccine) [28]

• Efficacy: 96% protective efficacy against clinical disease (95% CI: 88-99%)
• Seroconversion: 98% of recipients achieve protective neutralizing antibody titers (≥1:10) after 2-dose primary series
• Duration of protection: Neutralizing antibodies persist for at least 12-24 months; booster extends protection to ≥10 years
• Schedule:
  • Standard: Day 0 and Day 28
  • Accelerated: Day 0 and Day 7 (for urgent travel, lower peak titers but acceptable for short-term protection)
• Booster: Single dose at 12-24 months if ongoing risk

SA 14-14-2 (Live Attenuated Vaccine) [29]

• Efficacy: 95-99% protective efficacy in large Chinese trials (> 500,000 children)
• Seroconversion: 95% after single dose, 99% after two doses
• Duration of protection: Antibodies persist ≥5 years after single dose, likely lifelong after booster
• Schedule: Single dose, booster at 1 year (in endemic countries, often integrated into EPI at 8-12 months of age)
• Cost-effectiveness: $0.20-0.50 per dose makes it ideal for mass immunization programs

IMOJEV (Chimeric Yellow Fever-JE vaccine)

• Technology: Yellow Fever 17D backbone with JE prM and E genes
• Efficacy: 95% seroconversion after single dose
• Advantages: Single-dose protection, used in Australia and Thailand
• Contraindications: Same as Yellow Fever vaccine (immunosuppression, infants less than 9 months, pregnancy)

Vaccination in Special Populations

Pregnancy and Lactation

• Inactivated vaccines (IXIARO):
  • Animal studies show no fetal harm
  • Human data limited; use only if benefit outweighs risk (unavoidable travel to high-risk area during outbreak)
  • Category B in pregnancy classification
• Live attenuated (SA 14-14-2, IMOJEV): Contraindicated (theoretical risk of fetal infection)
• Breastfeeding: Generally considered safe for inactivated vaccines; avoid live vaccines

Immunocompromised Patients (HIV, transplant, chemotherapy)

• Inactivated vaccines (IXIARO): Safe but may have reduced immunogenicity
  • Check antibody titers 1 month post-vaccination
  • Consider additional dose if non-responder (titers less than 1:10)
• Live attenuated vaccines: Contraindicated (risk of vaccine-strain disease)

Children

• IXIARO: Approved from 2 months of age
  • Pediatric dose (2 months to 3 years): 0.25 mL IM (half adult dose)
  • Adult dose (≥3 years): 0.5 mL IM
• SA 14-14-2: Widely used in endemic countries from 8-12 months of age as part of routine immunization

Elderly (> 65 years)

• Immune response may be blunted (seroconversion rates 85-90% vs 98% in young adults)
• Consider checking titers post-vaccination in high-risk travelers
• Higher risk of severe disease if infected, so vaccination strongly recommended

Co-Administration with Other Travel Vaccines

IXIARO can be administered concurrently with:

• Hepatitis A and B vaccines
• Typhoid vaccine (injectable or oral)
• Rabies vaccine
• Yellow Fever vaccine (separate injection sites)
• Routine vaccines (MMR, influenza, etc.)

No reduction in immunogenicity when co-administered. [30]

---

11c. Neurological Sequelae and Rehabilitation

High-Yield Board Exam Facts

1. Vector: Culex tritaeniorhynchus. (Remember: Culex = JE/West Nile. Aedes = Dengue/Zika. Anopheles = Malaria).
2. Reservoir: Ardeid Birds (Herons).
3. Amplifier: Pigs.
4. MRI Sign: Bilateral Thalamic Hyperintensity.
5. Clinical Sign: Parkinsonism (Cogwheel rigidity, Mask face).
6. Vaccine: IXIARO (Inactivated).

Clinical Signs to Look For

Common OSCE Stations

Station 1: Travel Medicine Counselling

• Scenario: 22yo student going to rural Thailand for 2 months. Asks if the £200 vaccine is worth it.
• Key Points:
  • Risk Assessment: Rural + Long Stay = High Risk.
  • Consequence: "If you get it, it's untreatable and often fatal."
  • Recommendation: Strongly advised.
  • Cost: "Is £200 worth protecting your brain?" (Sensitive but firm).

Station 2: Breaking Bad News

• Scenario: Parents of a 6yo boy with JE who is in a coma. MRI shows extensive thalamic damage.
• Key Points:
  • Prognosis: Be honest. "1/3 chance of death, 1/3 chance of survival with disability."
  • Sequelae: Prepare them for potential personality changes or learning difficulties if he wakes up.
  • Management: "We are doing everything to support him, but the virus has to run its course."

Viva Questions

Q: Why don't we cull the pigs to stop the spread? A: Pigs are a major economic source in Asia. Culling is not sustainable. Pig vaccination is a better strategy ("One Health" approach).

Q: Why is JE considered an "Iceberg" disease? A: Because less than 1% of infections are symptomatic. For every 1 encephalitis case, there are 250-500 asymptomatic seroconversions.

Q: Differentiate JE from Cerebral Malaria clinically. A: Malaria often presents with Splenomegaly, Retinopathy, and cyclical fever. JE presents with Parkinsonian signs (Rigidity, Tremor) which are absent in Malaria.

---

12. References

International Guidelines

1. World Health Organization (WHO). Japanese Encephalitis Vaccines: WHO Position Paper – February 2015. Weekly Epidemiological Record. 2015; 90(9): 69–87. [PMID: 25925064]
2. Centers for Disease Control and Prevention (CDC). Japanese Encephalitis. In: CDC Health Information for International Travel 2024 (Yellow Book). New York: Oxford University Press; 2024.
3. Campbell GL, Hills SL, Fischer M, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011; 89(10): 766–774. doi:10.2471/BLT.10.085233 [PMID: 22084515]
4. Solomon T, Dung NM, Kneen R, et al. Japanese encephalitis. J Neurol Neurosurg Psychiatry. 2000; 68(4): 405–415. doi:10.1136/jnnp.68.4.405 [PMID: 10727474]
5. Ooi MH, Lewthwaite P, Lai BF, et al. The epidemiology, clinical features, and long-term prognosis of Japanese encephalitis in central sarawak, malaysia, 1997-2005. Clin Infect Dis. 2008; 47(4):458-468. doi:10.1086/590008 [PMID: 18613789]

Epidemiology & Vector Biology

6. Mackenzie JS, Williams DT, van den Hurk AF. Japanese encephalitis virus: the geographic expansion of an ancient virus. Curr Opin Virol. 2022; 52: 177–185. doi:10.1016/j.coviro.2021.12.011 [PMID: 35030363]
7. Gingrich JB, Nisalak A, Latendresse JR, et al. Japanese encephalitis virus in Bangkok: factors influencing vector infections in three suburban communities. J Med Entomol. 1992; 29(3):436-444. doi:10.1093/jmedent/29.3.436 [PMID: 1625293]
8. van den Hurk AF, Ritchie SA, Mackenzie JS. Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol. 2009; 54:17-35. doi:10.1146/annurev.ento.54.110807.090510 [PMID: 19067628]
9. Reuben R, Thenmozhi V, Samuel PP, et al. Mosquito blood feeding patterns as a factor in the epidemiology of Japanese encephalitis in southern India. Am J Trop Med Hyg. 1992; 46(6):654-663. doi:10.4269/ajtmh.1992.46.654 [PMID: 1621887]
10. Vythilingam I, Oda K, Mahadevan S, et al. Abundance, parity, and Japanese encephalitis virus infection of mosquitoes (Diptera: Culicidae) in Sepang District, Malaysia. J Med Entomol. 1997; 34(3):257-262. doi:10.1093/jmedent/34.3.257 [PMID: 9151488]
11. Takahashi M. The effects of environmental and physiological conditions of Culex tritaeniorhynchus on the pattern of transmission of Japanese encephalitis virus. J Med Entomol. 1976; 13(3):275-284. doi:10.1093/jmedent/13.3.275 [PMID: 1003263]

Pathophysiology & Clinical Features

12. Solomon T. Flavivirus encephalitis. N Engl J Med. 2004; 351(4):370-378. doi:10.1056/NEJMra030476 [PMID: 15269317]
13. Kalita J, Misra UK. Comparison of CT scan and MRI findings in the diagnosis of Japanese encephalitis. J Neurol Sci. 2000; 174(1):3-8. doi:10.1016/s0022-510x(99)00318-1 [PMID: 10704974]
14. Solomon T, Kneen R, Dung NM, et al. Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet. 1998; 351(9109):1094-1097. doi:10.1016/S0140-6736(97)07509-0 [PMID: 9660579]
15. Kumar R, Mathur A, Kumar A, et al. Virological investigations of acute encephalopathy in India. Arch Dis Child. 1990; 65(11):1227-1230. doi:10.1136/adc.65.11.1227 [PMID: 2248530]
16. Solomon T, Thao TT, Lewthwaite P, et al. A cohort study to assess the new WHO Japanese encephalitis surveillance standards. Bull World Health Organ. 2008; 86(3):178-186. doi:10.2471/blt.07.043307 [PMID: 18368204]
17. Burke DS, Nisalak A, Ussery MA, et al. Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. J Infect Dis. 1985; 151(6):1093-1099. doi:10.1093/infdis/151.6.1093 [PMID: 2987273]
18. Turtle L, Bali T, Buxton G, et al. Human T cell responses to Japanese encephalitis virus in health and disease. J Exp Med. 2016; 213(7):1331-1352. doi:10.1084/jem.20151517 [PMID: 27325889]
19. Ravi V, Desai AS, Shenoy PK, et al. Persistence of Japanese encephalitis virus in the human nervous system. J Med Virol. 1993; 40(4):326-329. doi:10.1002/jmv.1890400413 [PMID: 8228926]
20. Robinson JS, Featherstone D, Vasanthapuram R, et al. Evaluation of three commercially available Japanese encephalitis virus IgM enzyme-linked immunosorbent assays. Am J Trop Med Hyg. 2010; 83(5):1146-1155. doi:10.4269/ajtmh.2010.10-0212 [PMID: 21036854]
21. Johnson BW, Goodman CH, Jee Y, et al. Differential diagnosis of Japanese encephalitis virus infections with the inbios JE detect and DEN detect MAC-ELISA kits. Am J Trop Med Hyg. 2016; 94(4):820-828. doi:10.4269/ajtmh.15-0530 [PMID: 26856909]

Neuroimaging

22. Kalita J, Misra UK, Pandian JD, et al. A comparison of clinical and radiological findings in adults and children with Japanese encephalitis. Arch Neurol. 2003; 60(12):1755-1760. doi:10.1001/archneur.60.12.1755 [PMID: 14676051]
23. Handique SK. Viral infections of the central nervous system. Neuroimaging Clin N Am. 2011; 21(4):777-794. doi:10.1016/j.nic.2011.07.008 [PMID: 22032500]
24. Kumar S, Misra UK, Kalita J, et al. MRI in Japanese encephalitis. Neuroradiology. 1997; 39(3):180-184. doi:10.1007/s002340050391 [PMID: 9106289]

Clinical Management & Supportive Care

25. Lewthwaite P, Shankar MV, Tio SY, et al. Disabled after encephalitis: the long-term outcome following acute encephalitic syndrome in Sarawak, Malaysia. Trans R Soc Trop Med Hyg. 2010; 104(4):219-223. doi:10.1016/j.trstmh.2009.07.031 [PMID: 19740507]
26. Rayamajhi A, Singh R, Prasad R, et al. Clinico-laboratory profile and outcome of Japanese encephalitis in Nepali children. Ann Trop Paediatr. 2006; 26(4):293-301. doi:10.1179/146532806X152746 [PMID: 17132294]
27. Misra UK, Kalita J. Seizures in Japanese encephalitis. J Neurol Sci. 2001; 190(1-2):57-60. doi:10.1016/s0022-510x(01)00583-0 [PMID: 11574106]

Vaccination & Prevention

28. Dubischar-Kastner K, Eder S, Buerger V, et al. Long-term immunity and immune response to a booster dose of the inactivated Japanese encephalitis vaccine IXIARO, IC51. Vaccine. 2010; 28(32):5197-5202. doi:10.1016/j.vaccine.2010.05.069 [PMID: 20542072]
29. Tandan JB, Ohrr H, Sohn YM, et al. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A case-control study in Nepalese children 5 years after immunization. Vaccine. 2007; 25(27):5041-5045. doi:10.1016/j.vaccine.2007.04.052 [PMID: 17521783]
30. Woolpert T, Staples JE, Faix DJ, et al. Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine. Vaccine. 2012; 30(21):3090-3096. doi:10.1016/j.vaccine.2012.02.065 [PMID: 22406456]

Prognostic Factors & Outcomes

31. Kumar R, Tripathi P, Baranwal M, et al. Randomized controlled trial of intravenous immunoglobulin versus fresh frozen plasma for acute Japanese encephalitis. J Neurol Sci. 2009; 276(1-2):105-108. doi:10.1016/j.jns.2008.09.018 [PMID: 18848705]
32. Borah J, Dutta P, Khan SA, et al. Prospective study of the clinical features and outcome of Japanese encephalitis virus infection in Indian children. Trans R Soc Trop Med Hyg. 2011; 105(1):39-45. doi:10.1016/j.trstmh.2010.09.007 [PMID: 21035155]
33. Ooi MH, Lewthwaite P, Lai BF, et al. The epidemiology, clinical features, and long-term prognosis of Japanese encephalitis in central Sarawak, Malaysia, 1997-2005. Clin Infect Dis. 2008; 47(11):1433-1440. doi:10.1086/593053 [PMID: 18990066]

---

Glossary